Listen in as SCAI President James B. Hermiller, MD, MSCAI, shares more about his focus on radiation and occupational safety, and looks ahead to the upcoming SCAI Scientific Sessions, to be held May 1-3 in Washington, D.C.
Isatuximab as monotherapy for the treatment of patients with relapsed/refractory multiple myeloma demonstrated improved cancer outcomes and durable responses.
According to a case series of patients enrolled in the TAPUR trial, afatinib showed promising activity among patients with advanced solid tumors harboring neuregulin 1…
The authors present the case of a 56-year-old woman with left leg swelling and pain due to May-Thurner syndrome and an associated AVF that was…
The Disease State Update: Multiple Myeloma Disease State Hub from Oncology offers relevant news and insights for medical professionals.
Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
For dermatologists, the continued emergence of new targeted therapies requires careful patient selection and vigilance regarding long-term safety.
According to results from the phase 3 PRODIGE 51-FFCD-GASTFOX trial, the TFOX chemotherapy regimen in the first-line setting improved survival and response outcomes compared to…
The AVENTUS Trial successfully met its primary endpoints, demonstrating both safety and efficacy in the treatment of acute intermediate-risk pulmonary embolism (PE) patients.
The AVENTUS Trial successfully met its primary endpoints, demonstrating both safety and efficacy in the treatment of acute intermediate-risk pulmonary embolism (PE) patients.
In this feature interview, EP Lab Digest speaks with cardiac electrophysiologists Albert Sun, MD, and Jason Koontz, MD, PhD, about their experience streamlining retrograde aortic…
